Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume

Valneva SE (NASDAQ:VALN – Get Rating) saw unusually-strong trading volume on Friday . Approximately 1,729 shares traded hands during mid-day trading, a decline of 49% from the previous session’s volume of 3,396 shares.The stock last traded at $15.16 and had previously closed at $15.19.

Analyst Ratings Changes

Separately, HC Wainwright cut their price objective on shares of Valneva from $27.00 to $25.00 in a research note on Monday, December 5th.

Valneva Price Performance

The stock’s 50 day moving average price is $13.93 and its 200-day moving average price is $15.51. The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.57.

Valneva (NASDAQ:VALN – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $1.47. The firm had revenue of $157.92 million for the quarter, compared to the consensus estimate of $78.52 million. As a group, equities research analysts forecast that Valneva SE will post -1.19 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. General American Investors Co. Inc. bought a new position in Valneva in the 3rd quarter worth $3,768,000. Bank of America Corp DE bought a new position in Valneva in the 1st quarter worth $858,000. Jane Street Group LLC raised its holdings in Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, UBS Group AG bought a new position in Valneva in the 2nd quarter worth $31,000. 15.83% of the stock is currently owned by institutional investors.

Valneva Company Profile

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.